Autopsy report · NCT04405778

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

“Business decision unrelated to patient safety”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 4 years 10 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Takeda

Sponsor type

Industry

Conditions

Solid Tumors

Interventions

TAK-102

Participants

12

Sites

3

Countries

Japan

Trials that died the same way

• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
  “Business decision, not related to safety” (78% match in meaning)
• Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury
  “Based on a business decision unrelated to any safety concerns.” (72% match in meaning)
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
  “Company decision (not a safety issue)” (71% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (69% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.